I still expect LPTN to be the target of a reverse merger in due course. Investing in biotech companies with busted pipelines that are trading below net cash can be rewarding; however, achieving a gain that exceeds the opportunity cost depends to a large degree on luck.
Market Data 
Markets 
AI
